© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
Aspirin plus a DOAC may do more harm than good in some
REPORTING FROM ASH 2019
Related Articles
![1]()
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
December 8, 2019
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Reversal agents curb DOAC-related bleeding but deaths still high
December 8, 2019
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
Novel antiplatelet drug: Hope for efficacy without bleeding?
December 8, 2019
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events without increasing bleeding.
![1]()
Ticagrelor reversal agent looks promising
December 8, 2019
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.
